



ATTORNEY GENERAL OF TEXAS  
GREG ABBOTT

January 23, 2012

Mr. Kipling D. Giles  
Senior Counsel  
CPS Energy  
P.O. Box 1771  
San Antonio, Texas 78296

OR2012-01090

Dear Mr. Giles:

You ask whether certain information is subject to required public disclosure under the Public Information Act (the "Act"), chapter 552 of the Government Code. Your request was assigned ID# 442973.

The City Public Service Board of the City of San Antonio d/b/a CPS Energy ("CPS") received two requests for proposals, final contract, and evaluation documents pertaining to CPS's request for proposals for Pharmacy Benefit Manager. Although CPS takes no position as to whether the requested information is excepted under the Act, you state release of this information may implicate the proprietary interests of third parties. Accordingly, you state, and provide documentation showing, you notified Aetna, Inc. ("Aetna"); CaremarkPCS Health, L.L.C. ("Caremark"); Express Scripts, Inc. ("ESI"); H-E-B; Humana, Inc. ("Humana"); InformedRx, Inc. ("InformedRx"); Medco Health Solutions, Inc. ("Medco"); OptumRx, Inc. ("OptumRx") f/k/a Prescription Solutions; and Towers Watson Pennsylvania, Inc. ("Towers") of the request and of their right to submit arguments to this office as to why their information should not be released. *See* Gov't Code § 552.305(d); *see also* Open Records Decision No. 542 (1990) (determining statutory predecessor to section 552.305 permits governmental body to rely on interested third party to raise and explain applicability of exception to disclosure under Act in certain circumstances). We have received comments from Aetna, Caremark, ESI, Humana, InformedRx, Medco, OptumRx, and Towers. We have considered the submitted arguments and reviewed the submitted information.

Initially, we note CPS has not submitted the final contract for our review. Thus, to the extent the final contract existed when the present requests were received, we assume it has been released. If such information has not been released, then it must be released at this time. *See* Gov't Code §§ 552.301(a), .302; *see also* Open Records Decision No. 664 (2000) (if governmental body concludes that no exceptions apply to requested information, it must release information as soon as possible).

Next, we note an interested third party is allowed ten business days after the date of its receipt of the governmental body's notice under section 552.305(d) to submit its reasons, if any, as to why information relating to that party should be withheld from public disclosure. *See* Gov't Code § 552.305(d)(2)(B). As of the date of this letter, we have not received comments from H-E-B explaining why its information should not be released. Therefore, we have no basis to conclude H-E-B has a protected proprietary interest in the submitted information. *See id.* § 552.110; Open Records Decision Nos. 661 at 5-6 (1999) (to prevent disclosure of commercial or financial information, party must show by specific factual evidence, not conclusory or generalized allegations, that release of requested information would cause that party substantial competitive harm), 552 at 5 (1990) (party must establish *prima facie* case that information is trade secret), 542 at 3. Accordingly, CPS may not withhold any of the information at issue on the basis of any proprietary interest H-E-B may have in it.

We note Humana, ESI, and Medco seek to withhold information CPS has not submitted for our review. This ruling does not address information beyond what CPS has submitted to us for review. *See* Gov't Code § 552.301(e)(1)(D) (governmental body requesting decision from attorney general must submit copy of specific information requested). Accordingly, this ruling is limited to the information CPS submitted as responsive to the request for information. *See id.*

Aetna, Caremark, ESI, Humana, InformedRx, Medco, OptumRx, and Towers argue portions of their information are protected under section 552.110 of the Government Code, which protects (1) trade secrets, and (2) commercial or financial information, the disclosure of which would cause substantial competitive harm to the person from whom the information was obtained. *See id.* § 552.110(a), (b). Section 552.110(a) protects trade secrets obtained from a person and privileged or confidential by statute or judicial decision. *Id.* § 552.110(a). The Texas Supreme Court has adopted the definition of trade secret from section 757 of the Restatement of Torts. *See Hyde Corp. v. Huffines*, 314 S.W.2d 763 (Tex. 1957); *see also* ORD 552. Section 757 provides that a trade secret is

any formula, pattern, device or compilation of information which is used in one's business, and which gives him an opportunity to obtain an advantage over competitors who do not know or use it. It may be a formula for a chemical compound, a process of manufacturing, treating or preserving materials, a pattern for a machine or other device, or a list of customers. It differs from other secret information in a business . . . in that it is not simply information as to single or ephemeral events in the conduct of the business . . . . A trade secret is a process or device for continuous use in the operation of the business. . . . [It may] relate to the sale of goods or to other operations in the business, such as a code for determining discounts, rebates or other concessions in a price list or catalogue, or a list of specialized customers, or a method of bookkeeping or other office management.

RESTATEMENT OF TORTS § 757 cmt. b (1939); *see also Huffines*, 314 S.W.2d at 776. In determining whether particular information constitutes a trade secret, this office considers the Restatement's definition of trade secret as well as the Restatement's list of six trade secret factors.<sup>1</sup> RESTATEMENT OF TORTS § 757 cmt. b. This office must accept a claim information subject to the Act is excepted as a trade secret if a *prima facie* case for the exception is made and no argument is submitted that rebuts the claim as a matter of law. *See* ORD 552 at 5. However, we cannot conclude section 552.110(a) is applicable unless it has been shown the information meets the definition of a trade secret and the necessary factors have been demonstrated to establish a trade secret claim. *See* Open Records Decision No. 402 (1983).

Section 552.110(b) of the Government Code excepts from disclosure “[c]ommercial or financial information for which it is demonstrated based on specific factual evidence that disclosure would cause substantial competitive harm to the person from whom the information was obtained.” Gov’t Code § 552.110(b). Section 552.110(b) requires a specific factual or evidentiary showing, not conclusory or generalized allegations, that substantial competitive injury would likely result from release of the requested information. *See* ORD 661 at 5-6 (business enterprise must show by specific factual evidence that release of information would cause it substantial competitive harm).

Upon review, we find Caremark, ESI, Humana, InformedRx, Medco, and OptumRx have established some of their information constitutes trade secrets. Therefore, CPS must withhold this information, which we have marked, under section 552.110(a) of the Government Code. However, we note Medco has published some of the remaining information it seeks to withhold under section 552.110(a), including its drug formularies, on its website, making this information publically available. Because Medco has published this information, it has failed to demonstrate this information is a trade secret, and none of it may be withheld under section 552.110(a). In addition, we find Caremark, ESI, Humana, InformedRx, Medco, OptumRx, and Towers have failed to demonstrate any of the remaining information at issue meets the definition of a trade secret, nor have these companies demonstrated the necessary factors to establish a trade secret claim for this information. We

---

<sup>1</sup>The Restatement of Torts lists the following six factors as indicia of whether information constitutes a trade secret:

- (1) the extent to which the information is known outside of [the company];
- (2) the extent to which it is known by employees and other involved in [the company’s] business;
- (3) the extent of measures taken by [the company] to guard the secrecy of the information;
- (4) the value of the information to [the company] and [its] competitors;
- (5) the amount of effort or money expended by [the company] in developing the information;
- (6) the ease or difficulty with which the information could be properly acquired or duplicated by others.

RESTATEMENT OF TORTS § 757 cmt. b (1939); *see also* Open Records Decision Nos. 319 at 2 (1982), 306 at 2 (1982), 255 at 2 (1980).

note that pricing information pertaining to a particular contract is generally not a trade secret because it is “simply information as to single or ephemeral events in the conduct of business,” rather than “a process or device for continuous use in the operation of the business.” See RESTATEMENT OF TORTS § 757 cmt. b; *Huffines*, 314 S.W.2d at 776; ORD 319 at 3 (information relating to organization and personnel, professional references, market studies, qualifications, and pricing are not ordinarily excepted from disclosure under statutory predecessor to section 552.110). Thus, none of the remaining information may be withheld under section 552.110(a) of the Government Code.

Caremark also contends portions of its proposal are excepted under section 552.110(b) of the Government Code because release of the information at issue would harm CPS’s ability and the ability of other governmental entities to obtain qualified candidates in response to future searches. In advancing this argument, Caremark appears to rely on the test pertaining to the applicability of the section 552(b)(4) exemption under the federal Freedom of Information Act to third-party information held by a federal agency, as announced in *National Parks & Conservation Association v. Morton*, 498 F.2d 765 (D.C. Cir. 1974). The *National Parks* test provides that commercial or financial information is confidential if disclosure of information is likely to impair a governmental body’s ability to obtain necessary information in future. *National Parks*, 498 F.2d at 765. Although this office once applied the *National Parks* test under the statutory predecessor to section 552.110, that standard was overturned by the Third Court of Appeals when it held *National Parks* was not a judicial decision within the meaning of former section 552.110. See *Birnbaum v. Alliance of Am. Insurers*, 994 S.W.2d 766 (Tex. App.—Austin 1999, pet. denied). Section 552.110(b) now expressly states the standard to be applied and requires a specific factual demonstration that the release of the information in question would cause the business enterprise that submitted the information substantial competitive harm. See ORD 661 at 5-6 (discussing enactment of section 552.110(b) by Seventy-sixth Legislature). The ability of a governmental body to continue to obtain information from private parties is not a relevant consideration under section 552.110(b). *Id.* Therefore, we will consider only Caremark’s interest in its proposal.

Upon review of the submitted arguments under section 552.110(b), we find Aetna, ESI, Humana, InformedRx, Medco, and OptumRx have established some of their remaining information, including pricing information, constitutes commercial or financial information, the release of which would cause each company substantial competitive injury. Therefore, CPS must withhold the information we have marked under section 552.110(b) of the Government Code. However, as previously noted, Medco has published some of the remaining information it seeks to withhold, including its drug formularies, on its website, making this information publically available. Because Medco has published this information, it has failed to demonstrate how release of this information would cause it substantial competitive injury. Furthermore, we find Aetna, Caremark, ESI, Humana, InformedRx, Medco, OptumRx, and Towers have made only conclusory allegations that the release of any of the remaining information would result in substantial damage to their competitive positions. Thus, these third parties have not demonstrated substantial competitive injury would result from the release of any of the remaining information at issue. See ORD 661 (for information to be withheld under commercial or financial information

prong of section 552.110, business must show by specific factual evidence that substantial competitive injury would result from release of particular information at issue). Furthermore, we note Caremark was the winning bidder with respect to the request for proposals at issue, and the pricing information of a winning bidder is generally not excepted under section 552.110(b). This office considers the prices charged in government contract awards to be a matter of strong public interest. *See* Open Records Decision No. 514 (1988) (public has interest in knowing prices charged by government contractors). *See generally* Dep't of Justice Guide to the Freedom of Information Act 344-45 (2009) (federal cases applying analogous Freedom of Information Act reasoning that disclosure of prices charged government is a cost of doing business with government). Thus, CPS may not withhold any of the remaining information under section 552.110(b).

Section 552.101 of the Government Code excepts from disclosure "information considered to be confidential by law, either constitutional, statutory, or by judicial decision." Gov't Code § 552.101. This section encompasses information protected by other statutes. Caremark argues portions of its remaining information fit the definition of a trade secret found in section 1839(3) of title 18 of the United States Code, and indicates this information is therefore confidential under sections 1831 and 1832 of title 18 of the United States Code. *See* 18 U.S.C. §§ 1831, 1832, 1839(3). Section 1839(3) provides in relevant part:

(3) the term "trade secret" means all forms and types of financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs, prototypes, methods, techniques, processes, procedures, programs, or codes . . . if-

(A) the owner thereof has taken reasonable measures to keep such information secret; and

(B) the information derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable through proper means by, the public[.]

*Id.* § 1839(3). Section 1831 provides criminal penalties for the unauthorized disclosure of trade secrets to foreign governments, instrumentalities, or agents. *Id.* § 1831. Section 1832 provides criminal penalties for the unauthorized appropriation of trade secrets related to products produced for or placed in interstate or foreign commerce. *Id.* § 1832. We find Caremark has not demonstrated the information at issue is a trade secret under section 1839(3). Accordingly, we need not determine whether section 1831 or section 1832 applies, and CPS may not withhold any of the remaining information under section 552.101 on those bases.

We note some of the remaining information is subject to section 552.136 of the Government Code.<sup>2</sup> Section 552.136 states that “[n]otwithstanding any other provision of this chapter, a credit card, debit card, charge card, or access device number that is collected, assembled, or maintained by or for a governmental body is confidential.” Gov’t Code § 552.136. Accordingly, we find CPS must withhold the insurance policy numbers and bank account number we have marked under section 552.136 of the Government Code.


ESI, InformedRx, and Medco assert their information is subject to copyright. We note some of the other materials at issue may be protected by copyright. A custodian of public records must comply with the copyright law and is not required to furnish copies of records that are copyrighted. Open Records Decision No. 180 at 3 (1977). A governmental body must allow inspection of copyrighted materials unless an exception applies to the information. *Id.*; see Open Records Decision No. 109 (1975). If a member of the public wishes to make copies of copyrighted materials, the person must do so unassisted by the governmental body. In making copies, the member of the public assumes the duty of compliance with the copyright law and the risk of a copyright infringement suit.

In summary, CPS must withhold the information we have marked under sections 552.110 and 552.136 of the Government Code. The remaining information must be released, but any information protected by copyright may only be released in accordance with copyright law.

This letter ruling is limited to the particular information at issue in this request and limited to the facts as presented to us; therefore, this ruling must not be relied upon as a previous determination regarding any other information or any other circumstances.

This ruling triggers important deadlines regarding the rights and responsibilities of the governmental body and of the requestor. For more information concerning those rights and responsibilities, please visit our website at [http://www.oag.state.tx.us/open/index\\_orl.php](http://www.oag.state.tx.us/open/index_orl.php), or call the Office of the Attorney General’s Open Government Hotline, toll free, at (877) 673-6839. Questions concerning the allowable charges for providing public information under the Act must be directed to the Cost Rules Administrator of the Office of the Attorney General, toll free, at (888) 672-6787.

Sincerely,



Jennifer Luttrall  
Assistant Attorney General  
Open Records Division

JL/dls

---

<sup>2</sup>The Office of the Attorney General will raise a mandatory exception on behalf of a governmental body, but ordinarily will not raise other exceptions. Open Records Decision Nos. 481 (1987), 480 (1987), 470 (1987).

Ref: ID# 442973

Enc. Submitted documents

c: Requestors  
(w/o enclosures)

Mr. Mark R. Chulick  
Regional Counsel  
Law and Regulatory Affairs  
Aetna, Inc.  
2777 Stemmons Freeway  
Dallas, Texas 75207  
(w/o enclosures)

CaremarkPCS Health, L.L.C.  
c/o Mr. Robert H. Griffith  
Foley & Lardner, L.L.P.  
321 North Clark Street, Suite 2800  
Chicago, Illinois 60610-4764  
(w/o enclosures)

Express Scripts, Inc.  
c/o Ms. Melissa J. Copeland  
Schmidt & Copeland, L.L.C.  
P.O. Box 11547  
Columbia, South Carolina 29211  
(w/o enclosures)

Mr. David Hughes  
H-E-B  
c/o Mr. Kipling D. Giles  
Senior Counsel  
CPS Energy  
P.O. Box 1771  
San Antonio, Texas 78296  
(w/o enclosures)

Humana, Inc.  
c/o Ms. Rachel K. Padgett  
McGinnis, Lochridge & Kilgore, L.L.P.  
600 Congress Avenue, Suite 2100  
Austin, Texas 78701  
(w/o enclosures)

Mr. Clifford E. Berman  
Senior Vice President and General Counsel  
InformedRx, Inc.  
2441 Warrenville Road, Suite 610  
Lisle, Illinois 60532  
(w/o enclosures)

Medco Health Solutions, Inc.  
c/o Mr. Richard L. Josephson  
Baker Botts, L.L.P.  
One Shell Plaza  
910 Louisiana  
Houston, Texas 77002-4995  
(w/o enclosures)

OptumRx, Inc.  
c/o Mr. Darren L. McCarty  
Alston & Bird, L.L.P.  
2828 North Harwood Street, Suite 1800  
Dallas, Texas 75201-2139  
(w/o enclosures)

Mr. Michael J. Rodriguez  
Senior Consultant  
Towers Watson Pennsylvania, Inc.  
1221 McKinney, Suite 2600  
Houston, Texas 77010-1006  
(w/o enclosures)